Doxycycline calcium

Cat. No.: HY-N0565C: FAQs
Data Sheet Handling Instructions

Molarity Calculator

Doxycycline calcium, an antibiotic, is an orally active and broad-spectrum metalloproteinase (MMP) inhibitor. Doxycycline calcium shows antibacterial activity and anti-cancer cell proliferation activity.

For research use only. We do not sell to patients.

Doxycycline calcium Chemical Structure

CAS No. : 94088-85-4

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Doxycycline calcium:

Doxycycline hyclate

Other Forms of Doxycycline calcium:

Doxycycline hyclate In-stock
Doxycycline-d₃ (hyclate) (major) Get quote
Doxycycline Get quote
Doxycycline hydrochloride Get quote
Doxycycline monohydrate Get quote

91 Publications Citing Use of MCE Doxycycline calcium

: Doxycycline calcium purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2016 Jun 28;376(1):188-96. [Abstract]; Doxycycline inducible shRNA can effectivly knockdown the expression of AKT in HCC cells. Cells are treated with 100ng/mL Doxcycline and cultured for the indicated times.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All MMP Isoform Specific Products:

View All Isoforms

MMP-1 MMP-2 MMP-3 MMP-8 MMP-9 MMP-13 MMP-14 MMP-17 ADAM10 ADAM17 MMP-7 MMP-12 MMP-10 MMP ADAM8

View All Antibiotic Isoform Specific Products:

View All Isoforms

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

View All Parasite Isoform Specific Products:

View All Isoforms

Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

Biological Activity
Purity & Documentation
References
Customer Review

Description

Doxycycline calcium, an antibiotic, is an orally active and broad-spectrum metalloproteinase (MMP) inhibitor^[1]. Doxycycline calcium shows antibacterial activity and anti-cancer cell proliferation activity^[1]^[2]^[3]^[4]^[5].

IC₅₀ & Target

Tetracycline

In Vitro

Doxycycline calcium (0.01-10 µg/mL, 4 d) affects growth of glioma cells only under high concentrations^[2].
Doxycycline calcium (0.01-10 µg/mL, 24 h) decreases MT-CO1 protein content with concentrations of 1 µg/mL and higher in SVG cells^[2].
Doxycycline calcium (100 ng/mL, 1 µg/mL; 24 h) reduces proliferation of human cell lines^[4].
Doxycycline calcium (0-250 μM, 72 h) inhibits cell viability of breast cancer cells ^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	LNT-229, G55, and U343 glioma cells
Concentration:	0.01, 0.1, 1 or 10 µg/mL
Incubation Time:	4 days
Result:	Affected growth of glioma cells only under high concentration (10 µg/mL).

Cell Viability Assay^[2]

Cell Line:	SVG cells
Concentration:	0.01, 0.1, 1 or 10 µg/mL
Incubation Time:	24 hours
Result:	Decreaseed MT-CO1 protein content with concentrations of 1 µg/mL and higher.

Cell Proliferation Assay^[4]

Cell Line:	MCF 12A, 293T cells
Concentration:	100 ng/mL, 1 µg/mL
Incubation Time:	96 hours
Result:	Caused reduced proliferation of MCF 12A and 293T cells at 1 µg/mL.

Cell Viability Assay^[5]

Cell Line:	MCF-7, MDA-MB-468 cells
Concentration:	0-250 μM
Incubation Time:	72 hours
Result:	Inhibited breast cancer cells in a dose-dependent manner with IC₅₀ values for MCF-7 and MDA-MB-468 of 11.39 μM and 7.13 μM respectively.

In Vivo

Modeling ON-OFF system for gene expression^[6]^[7]

Background

Doxycycline is often used as an inducer in molecular biology research to induce gene expression. In cells or model animals that have constructed a Tetracycline (Tet; HY-A0107) inducible expression (Tet-ON/Tet-OFF) system, the expression of the target gene can be precisely controlled by adding or removing Doxycycline. Doxycycline can act as an inhibitor of transcriptional activation in the Tetracycline (Tc)-controlled transactivation (tTA) system, and as an inducer of transcriptional activation in the "reverse tTA' system. Doxycycline and Tetracycline both act systemically after being absorbed by the upper gastrointestinal tract. In comparison, the main advantage of Doxycycline is that it has a longer activity and can be taken twice or once a day. Although the peak concentrations of the two are similar, Doxycycline takes a shorter time to reach peak concentration and has a significantly longer half-life ^[6]^[7]^[8].

Specific Mmodeling Methods

Rat^[8]: male • adult middle-aged (12-month-old) • Sprague-Dawley rats
Administartion (for GDNF regulation): 3g/kg (Doxycycline; HY-N05655) (dietary with regular food) • po once daily for 6 days • monitored every day

Note

1. In this study^[7], a recombinant adeno-associated virus (rAAV)-based bicistronic tetracycline (tet)-OFF construct was used for dynamic control of GDNF (target gene) expression during long-term expression.
2. 3g/kg dietary DOX produced DOX serum levels equivalent to 1mg/ml DOX in drinking water.

Modeling Record

(1) The expression level of the target gene decreases; (2) The positively correlated phenotype corresponding to the target gene is alleviated.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6-month-old female Heterozygous Col3a1-deficient (HT) mice^[3]
Dosage:	200 or 800 mg/kg
Administration:	Oral gavage; 200 or 800 mg/kg; once daily; 3 months
Result:	Reduced MMP-9 activity in a dose-dependent manner.

Clinical Trial

Molecular Weight

524.59

Formula

C₂₂H₂₄Ca₂N₂O₈

CAS No.

94088-85-4

SMILES

O=C(C(C1=O)=C(O)[C@@H](N(C)C)[C@]2([H])[C@@H](O)[C@]3([H])[C@@H](C)C4=C(C(C3=C(O)[C@@]21O)=O)C(O)=CC=C4)N.[Ca].[Ca]

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Eusebio Manchado, et al. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature. 2016 Jun 30;534(7609):647-51. [Content Brief]

[2]. Anna-Luisa Luger, et al. Doxycycline Impairs Mitochondrial Function and Protects Human Glioma Cells from Hypoxia-Induced Cell Death: Implications of Using Tet-Inducible Systems. Int J Mol Sci. 2018 May 17;19(5):1504. [Content Brief]

[3]. Wilfried Briest, et al. Doxycycline ameliorates the susceptibility to aortic lesions in a mouse model for the vascular type of Ehlers-Danlos syndrome. J Pharmacol Exp Ther. 2011 Jun;337(3):621-7. [Content Brief]

[4]. Ethan Ahler, et al. Doxycycline alters metabolism and proliferation of human cell lines. PLoS One. 2013 May 31;8(5):e64561. [Content Brief]

[5]. Le Zhang, et al. Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer. Cell Cycle. 2017 Apr 18;16(8):737-745. [Content Brief]

[6]. Manfredsson FP, et al. Tight Long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector. Mol Ther. 2009 Nov;17(11):1857-67. [Content Brief]

[7]. Kistner A, et al. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10933-8. [Content Brief]

[8]. Niv Y. Doxycycline in Eradication Therapy of Helicobacter pylori--a Systematic Review and Meta-Analysis. Digestion. 2016;93(2):167-73. [Content Brief]